Allergy

Avapritinib shows significant long-term benefits for indolent systemic mastocytosis while maintaining a favorable safety profile.

A study shows children in remission can safely consume peanuts without daily dosing, supporting remission as the primary treatment goal over desensitization.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

Real-world data show epinephrine nasal spray achieved an 89.2% success rate in treating anaphylaxis, nearly identical to the injection’s response rate.

Stay updated with the latest healthcare breakthroughs, including FDA news and the voluntary withdrawal of obeticholic acid, in this week's essential news roundup.

Akin discussed updated data on elenestinib from the HARBOR trial in indolent systemic mastocytosis.

In over 500 patients, a single dose of neffy achieved an 89% success rate, matching injection outcomes and supporting its use as a needle-free alternative.

Regeneron's innovative antibody therapies show promising results in alleviating cat and birch allergies.

A study shows that sex modifies HRQL outcomes in peanut OIT: males benefit most from active treatment, while females show strong placebo gains.

Cluster protocol VIT demonstrates high efficacy in children with venom allergies, showing low systemic reactions and strong protection against re-stings.

Upstream Bio’s VIBRANT trial finds verekitug, a monoclonal antibody binding to the TSLP receptor, reduces nasal polyps in patients with CRSwNP.

This month in review features the top 5 allergy news in August 2025, including FDA approvals, updated guidelines, and emerging research.

The basophil activation test shows the greatest accuracy in predicting allergic reactions to baked and fresh cow’s milk, reducing the need for oral food challenges in children.

Research links Treg activity, B-cell suppression, and gastrointestinal immune regulation to the success and failure of peanut oral immunotherapy.

WAO’s updated framework adds mixed N-ERD, mixed NECD, and extends the pediatric term NIUAA to adults.

Study highlights risk factors and diagnostic accuracy for immediate-type local anesthetic allergy in children.

Stay updated with the latest healthcare breakthroughs, including FDA news and new cardiology research, in this week's essential news roundup.

MGH investigators confirmed the reliability of the Drug Allergy History Tool (DAHT), which outperformed EHR documentation in completeness.

The FDA has approved Ionis Pharmaceuticals' donidalorsen to prevent HAE attacks in adults and children over 12 years.

A discrete choice experiment revealed food allergy treatment preferences among adolescents, with efficacy ranking as the most important attribute.

A new advisory highlights cephalexin’s efficacy and low cross-reactivity risk, supporting its safe use in patients with penicillin allergy.

Survey and RESONATE trial data suggest a -0.22-point drop in the Combined Symptom and Medication Score signal meaningful benefit.

A study links the use of nasal corticosteroids to a greater risk of SARS-CoV-2 infection in adults, but not in children.

An audio recap of the top 5 stories in healthcare news from the week of 08/03-08/09.

Stay updated with the latest healthcare breakthroughs, including an FDA approval and new clinical trial data, in this week's essential news roundup.